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The goal governing dosage schedules for the chemotherapy of gastrointestinal cancer has been , in
general , to induce significant drug
toxicity in order to insure maximum therapeutic effect. The pursuit of maximum therapeutic effect
led logically to the development of
"Life Islands" which permit the isolated, relatively germ-free care of
patients treated with intensive chemotherapy. However, intensive chemotherapy may have deleterious effects on patients other than that of
increased susceptibility to infection.
It is, therefore, important to be
aware of the alternative approaches
implied in a recent analysis of data
obtained from the Eastern Clinical
Drug Evaluation Program ( CDE P) .
In this cooperative study, Bross et
al. (1966a, b, c) have shown that
patients manifesting drug toxicity
do not necessarily show a greater
frequency of tumor regression than
do patients without toxicity.
In the CDE P program a total of
956 patients were treated with 5fluorouracil ( 5-FU), dimethylurethamine (AB-132), mitomycin C,
chlorambucil , and 6-mercaptopurine (6-MP) in a 60-day study of
objective response. There was no
increase in tumor response with
high toxicity scores. In fact, the
patients with the greatest toxicity
showed a somewhat lower tumor
response. These data (Ausman,
1965; 1966 ; Bross, 1965; Bross et
* Supported by grant CY 2821 ,
U .S.P.H.S.
MCV QUARTERLY 3(2): 119-126, 1967

al., 1966a, b, c) suggest that overt
toxicity may not always be necessary to obtain an oncolytic effect.
This is further supported by a recent study of the Eastern Solid Tumor Group which compared 5-FU,
fluorodeoxyuridine (FUDR), and
methotrexate (MTX) at dose levels
producing comparable toxicity in
a group of patients with colon-rectal and breast cancer (Hall, in
press; Schneiderman and Krant,
1966). With increased toxicity a
plateau was reached beyond which
no significant further regression of
tumor could be obtained, and survival , despite tumor response, was
shortened in comparison to those
patients showing tumor response
but minimal drug toxicity (fig. 1) .
These observations as well as
those of Ansfield ( 1964) and others
(Cudmore and Groesbeck, 1964;
Groesbeck and Cudmore, 1963)
are supported by animal data
(Louis, 1965) and suggest that it
is not necessary to take patients to
toxic drug levels to achieve a significant remission. Such data should
reinforce our awareness of the possible deleterious effects of drug action on survival and remind us that
the gain afforded by tumor regression can be lost in the morbidity
and mortality induced by drugs.
The Eastern CDEP data suggest
that 5-FU and mitomycin C can
produce significant therapeutic effects without severe toxicity (Ausman, 1965; 1966; Bross, 1965;
Bross et al., 1966a, b, c). Therefore, it is important to avoid severe
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diarrhea, stomatitis, and marrow
depressions with white counts below 3,000/ mms or platelet counts
below 75,000/ mm 3 • When used this
way, 5-FU becomes of more general clinical usefulness in gastrointestinal cancer.
A renewed interest in alkylating
agents has resulted from observations indicating objective tumor regression ( > 50 % shrinkage) in
colon-rectal cancer with AB-132 (8
of 33), gastric cancer with AB-132
and chlorambucil ( 6 of 26), and
pancreatic cancer with AB-132 and
chlorambucil ( 6 of 8) in a study
by the Eastern CDEP (Ausman,
1965; 1966; Bross, 1965; Bross et
al., 1966a, b, c).
Chlorambucil showed no activity
in 15 patients with rectal cancer,
while 5of12 responded toAB-132.
Chlorambucil was given by mouth
and appeared to be most effective
in the upper gastrointestinal tract.
Unfortunately, this study as performed by the Eastern CDEP was
non-comparative and limited to
only two months of observation in
ambulatory patients. More critical
studies of these agents need to be
done. In the meantime, the ease
with which chlorambucil can be
given makes it worthy of serious
consideration as a useful agent in

gastric and pancreatic cancer, although its superiority to other alkylating agents has not been clearly
shown. Similarly, AB-132 or another parenteral alkylating agent
can be used in colon-rectal cancer.
Chemotherapy Combined
with Surgical Treatment
Laboratory evidence has supported the usefulness of adjuvant
prophylactic chemotherapy at the
time of surgery in the absence of
known disease. However, the clinical applications of this evidence
have shown puzzling results. There
is no improvement in recurrence
rates in men with colon-rectal cancer who received high-dose thioTEP A (0.8 mg/kg) at the time of
surgery, although women show a
significantly increased survival time
(U.C.L.A. Statistical Unit, 1965) .
In this study a high dose, with its
increased mortality and morbidity,
was felt necessary. Fluorodeoxyuridine (FUDR) used as an adjuvant
by the Veterans Administration
study shows no significant difference in recurrence rate at 30
months (personal communication,
M. W. Wolcott, 1965). These
studies await simultaneous controls
but evidence supports the possibility
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Fig. 1-Colon and rectum cancer. Eastern group double blind, 3 drug study (all
drugs combined). Data and graph courtesy of M.A. Schneiderman, M. J. Krant,
and T. C. Hall of the Eastern Solid Tumor Group. A major portion of this data
was presented in Cancer Chemotherapy Rept. 50: 107-112, 1966.
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that repeated 5-FU administration
increases the survival of patients
with occult tumor left behind.
Recently, Mackman and Curreri
( 1967) reported the results of a
"second-look procedure" evaluating
patients who had curative resections
for colon cancer but who showed
positive mesenteric node or serosal
involvement at the time of "curative" resection. Post-operatively,
these patients were given 5-fluorouracil for four or more courses
prior to their "second-look," one
year post operatively. Twenty patients were examined, 17 of which
had no tumor at the end of this oneyear period. An additional 11 patients who had direct extension to
adjacent organs or structures, who
were treated with only palliative
resection, were examined following
four to 10 courses of 5-fluorouracil.
Seven of these patients were free of
tumor, and three had tumor which
was removed for possible "cure."
This experience has recently been
supported by a report by Rousselot
et al. (1967, in press) who have reported on the survival of patients
over a five-year period following
the effectiveness of both intraluminal 5-fluorouracil administration
and systemic intravenous 5-fluorouracil in the post-ope.rative period.
This was a comparative study between nitrogen mustard and 5-fluorouracil. Adjuvant nitrogen mustard
had no effect on statistics regarding
recurrence rate. However, for 5fluorouracil in those patients who
had nodes (stage 3) significant improvement appeared. At five years
the survival rates were 65 % for
the 5-fluorouracil treated versus
32% in a nationwide control series
and 26 % in the St. Vincent's Hospital control series. There was no
apparent imorovement in survival
rates in st:ige 1 and 2 colon cancer
cases (negative nodes) as compared
to those seen on the basis of the
nationwide avernges and this reflects the over all effectiveness of
surgery in earlv colon cancer.
These studies despite the lack of
concomitant controls point out the

possible usefulness of an adjuvant
drug in the treatment of colon carcinoma particularly when known
tumor is left behind.
The value of massive intermittent
chemotherapy in the absence of
clinical disease as applied to acute
leukemia is a proven one (Hananian, Holland, and Sheehe, 1965),
but proof of an analogous situation
in colon-rectal cancer is only suggestive and requires further data.
A study of this kind for gastric and
bowel cancer using repeated courses
of cytoxan or mitomycin C is being
conducted in Europe (Karrer,
I 964a and b), and the results
should be of great interest when
they become available.
Wood et al. ( 1961) and others
(Cliffton and Agostino, 1963;
Koike, 1964) found a decrease in
the viability of circulating tumor
cells following the administration of
fibrinolysins or anticoagulants. The
adjuvant anti-tumor action of anticoagulants has not been explored
at the clinical level, but there are
controversial retrospective epidemiological data that suggest that cancer patients who received anticoagulants for post-surgical phlebitis
or coronary disease may have
shown an increase in tumor-free
survival time (Michaels, 1964) .
Based on this evidence, a study using heparin or fibrinolysin in the
postoperative period deserves serious consideration.
Regional perfusion has limited
value except in very special cases
(e.g., primary or metastatic disease
to liver) and may not offer more
palliation than is produced by systemic drug administration. However, the aggressive approach of
repeated intra-arterial administration of cytoxan and 5-FU by Bierman's group (Mesler, Winer, and
Bierman, 1965) deserves closer attention as does the work of Sullivan et al. (196'i) on prolonged
intra-arterial infusions.
The frequency of cancer cell
seeding in abdominal wounds has
led to the development of animal
screening methods to develop ef-

fective agents for wound irrigation
that would kill tumor cells. The
clinical use of monoxychlorosene
(Chlorpactin XCB) and mechlorethamine (HN,) and Thiotepa
(TSPA) followed on these observations. Despite the demonstrated
optimal activity of Na Hypochlorite and HN, as tumorcidal agents
in an animal tumor implantation
screen, long-term follow-up of head
and neck cancer patients receiving
post-operative wound irrigation with
these agents has shown accelerated
tumor take in the irrigated area
when compared to wound washing
with normal saline (Mukhtar et al.,
1963). More recent five-year survival data fully supports these observations. These studies indicate
that so called "topical chemotherapy" or "cytocidal wound irrigation" and should be absolutely contraindicated in the treatment of
gastrointestinal cancer until long
term follow-up indicates the efficacy of newer agents.
Radiotherapy Adjuvant
Chemotherapy

Radiotherapy in combination
with chemotherapy for synergistic
or additive effect has a valid rationale, based on data of responsive
animal tumors, when combined
with AB-132 (Regelson and Pierucci, 1964), 5-FU (Heidelberger
and Ansfield, 1963; Baclesse, Duplan, and Romer, 1964), or mitomycin C (Baclesse et al., 1964).
Results from past clinical studies
of this type are difficult to analyze
owing to the absence of concomitant controls. Jn addition, such large
doses of both drugs and radiation
were used that the therapeutic gain
possible through a more judicious
selection of dosage levels may have
been lost. One cannot expect patients with advanced cancer to
show increased survival time when
treated with comhinations of radiation or drugs that would result in
severe debilitation from either
agent alone. Despite these difficulties there are reports of increased
survival for patients with cancer of
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the pancreas or stomach treated
with 5-FU in conjunction with
radiation (Moertel et al., 1965).
The current Veterans Administration long-term continued study
which uses combinations of FUDR
with radiation may give a more
definitive answer, but systemic or
local effects on host resistance
could nullify the anti-tumor effect.
New Approaches to
Chemotherapy

Of particular interest are drug
combinations which may act synergistically or additively by interfering with alternative metabolic
pathways to eliminate the resistant
tumor population. Most of the studies reported so far are preliminary
and have not unequivocally demonstrated the virtues of combination chemotherapy in gastrointestinal cancer over the action of single
agents. A report of regression in a
pancreatic and epidermoid cancer
with the combination of 6-thioguanine with duazomycin A is encouraging and is based on sound rationale (Lefkowitz et al. , 1965) .
Animal data in the area of collateral sensitivity has not been systematically applied to human tumors. The results of one collateral
sensitivity study that could be applied immediately demonstrated that
a 5-FU resistant tumor in rodents
showed increased response to alkylating agents (Rutman, 1964). To
my knowledge this observation,
which calls for the use of an alkylating agent after failure to respond
to 5-FU, has not been tested
clinically. Similarly, there are
laboratory observations that uracil
mustard makes transplanted Sarcoma-180 tumor cells in mice more
sensitive to the anti-tumor action
of 6-thioguanine (Booth, Creasey,
and Sartorelli, 1964). Reports of
synergistic inhibition of S-180 by
mitomycin C and 6-thioguanine or
5-FU (Sartorelli and Booth, 1964)
are also clinically interesting, since
the clinical pharmacology of these
agents is well known.
A study is warranted on the use
122

of methotrexate in 5-FU resistant
patients based on the hypothesis
that the resistant tumor may be dependent on a de novo pathway of
thymidylate synthesis (Welch,
1963). However, Weiss and Jackson (1961) gave patients with gastrointestinal tract cancer MTX ( 5
mg orally per day) following 5-FU
and found no evident therapeutic
gain. More recently evidence has
accrued that MTX can increase the
level of thymidylate synthetase in
human leukemia (Roberts, 1966) .
Thus pretreatment with MTX may
deleteriously effect the response of
tumor cells to 5-FU.
Suitable for more immediate
study is the verification of suggested
evidence in man that glucose enhances 5-FU therapeutic effect
(Gotto, Belkhode, and Touster,
1964; Kessel , 1966; Lemon et al. ,
1963). lnosine (Gotto et al., 1964)
or adenosine (Kessel, 1966) also
results in increased tumor-cell uptake of 5-FU. These observations
may have clinical bearing and
should be tested in comparative
studies.
The importance of varied dosage
regimens is seen in the observations
that the prolonged intravenous administration of 5-FU is less toxic
than rapid drug administration .
However, any therapeutic gains
from prolonged infusion may be
offset by the convenience of rapid
intravenous injection and greater
control of dosage. Moertel et al.
(1964) have found no improvement in therapeutic results with
5-FU in prolonged intravenous administration as opposed to the
single rapid daily loading program.
Similar anti-tumor results, but with
considerable decrease in toxicity,
have now been observed clinically
by Ansfield (1964) using 12 mg/
kg/ day for four days as compared
to the earlier program of 15 mg/
kg/ day for four days, and the lower
dose should clearly be the one of
choice. Furthermore, the selection
of patients for treatment with 5-FU
should exclude severely debilitated
patients, since such patients show a
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decreased drug tolerance. This is
supported by data in the nutritionally deprived rat (Wolberg and
Curreri, 1960). In using 5-FU, it
is well to remember that reports of
a high order of regression such as
that of Vaitkevicius et al. ( 1961) ,
objective regression in 20 of 55 patients with adenocarcinoma of the
large bowel, are tempered by the
observation that regression was
clinically worthwhile in a small proportion and even that occurred at
the expense of severe toxicity in
many patients. However, as discussed earlier, the evidence that responses can be seen in the absence
of discomforting clinical toxicity or
serious hematopoietic depression indicates that 5-FU might be given
to advanced cancer patients for
shorter periods and at lower dosage
to avoid toxicity. In such a study
Young et al. (1960) obtained responses in 10 % to 15 % of patients with bowel cancer with total
dosage ranging from 30 to 150 mg/
kg. Similar results have been obtained by Ansfield ( 1964) and others (Cudmore and Groesbeck,
1964).
The topical administration of
5-FU in a 10 % ointment base has
resulted in the disappearance of
metastatic cutaneous adenocarcinoma of the bowel without damage
to normal skin (Klein et al. 1965).
This observation, while limited in
its application, is pertinent to a consideration of using local 5-FU for
palliation of recurrent or residual
tumor. Up to 10 % of 5-FU is adsorbed by the gastrointestinal lining
of the tumor segment (Cole, 1963) .
Patients have tolerated up to 8 mg/
kg/day P .O. for up to six weeks
with gastrointestinal side effects occurring, on an average, in 18 days
and hematologic toxicity in 21 days
(Ellison, 1962). Although anti-tumor effects have been seen (Cole,
1963; Ellison, 1962; Kennedy and
Theologides, 1961; Khung, 1965) ,
the virtues of local intraluminal
instillation of 5-FU into tumorinvolved segments of bowel in
prophylactic or adjuvant studies

have not been adequately explored.
There are other agents becoming
available, and reports of new drugs
are awaited with interest. For example, antibiotics which behave
similarly to actinomycin D, such
as chromomycin A., olivomycin,
and mithramycin, which combine
with DNA to impede RNA synthesis (Ward, Reich, and Goldberg,
1965) may show promise (Mayevsky, 1964; Akopliants, 1962). Studies of ethidium and daunomycin
which have effects in common on
purine metabolism (Ward et al.,
1965) may prove useful. 6-Azauridine has been reported to produce
objective improvement in one of
three gastric and pancreatic carcinoma patients for periods of four
to five months (Welch et al., 1960).
There is fairly extensive Japanese literature regarding the clinical efficacy of a variety of porphyrin derivatives (Fukuyama, Tsuji,
and Nakagawara, 1963; Matsubara et al., 1963; Tazaki, 1962;
Tazaki and Fume, 1961). Hematoporphyrin mercury was reported
to inhibit nucleic acid metabolism
in stomach and intestine with an
increased uptake of the drug in tumor as compared with normal tissue. This compound was said to
produce objective and subjective
improvement in several patients
with gastrointestinal cancer (Fukuyama et al., 1963; Tazake, 1962;
Tazaki and Fume, 1961 ) . Similar
effectiveness was reported for a cob alt protoporphyrin preparation
(Fukuyama et al., 1963; Matsubara
et al., 1963). It is hoped that an
evaluation of these reports will not
take as long as those studies involving mitomycin C.
In early clinical trials the toxicity
which eventually blunts the initi al
enthusiasm of extended trial is frequently minimized. It was this type
of experience with mitomycin C
that delayed its entry into clinical
practice. Much of the Japanese
work with mitomycin C has been
associated with its administration as
an adjuvant at the time of surgery
(Frank and Osterberg, 1960; Os-

ada, 1963; Shiba, 1963). A threeyear survival rate of 66 % in comparison with a control of 30 % was
found by Osada et al. ( 1963) in
patients with gastric cancer who
had undergone palliative surgical resection. Skepticism is in order, since
one can also find reports indicating
increased survival time in patients
treated after gastrectomy with
mechlorethamine, nitromin, sarkomycin, or carzinophilin (lshiyama,
1965), P32 and TSPA (Osada,
1963). Hoerr ( 1965) has found an
11 % five-year survival rate in palliative surgical resection for gastric
cancer even in the absence of chemotherapy. Similar results have been
obtained in untreated bile duct tumors (Lippman, McDonald, and
Longmire, 1959). Therefore, isolated case reports of long term responses must be analyzed carefully,
as they may be related to the selection of a group of long-term survivors that are present in any given
gastrointestinal tumor population.
Varied approaches to dosage and
timing of drug administration are
important in any program of drug
evaluation. This was dramatically
demonstrated when the "old" drug,
methotrexate, was used in a new
way which led to the cure of choriocarcinoma (Li, Hertz, and Spencer, 1956) . Modified methotrexate
regimens increased survival of children with acute leukemia (Selawry
and James, 1965; Acute Leukemia
Group B, 1965) and are producing
responses in bronchogenic carcinoma (Ross and Selawry, 1965)
and bowel cancer (Condit, Shnider,
and Owens, 1962). The twice-aweek administration of methotrexate (0.25 mg/kg or 0.6 mg/kg) for
gastrointestinal cancer is under
study by the Eastern Solid Tumor
Group, and the results are awaited
with interest.
As suggested by this review,
much remains to be done in the
chemotherapeutic approach to gastrointestinal cancer. The conservative use of 5-FU and alkylating
agents have a place provided that
severe toxicity is avoided. The sur123
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gical adjuvant use of 5-FU has a
rational basis and its application to
patients with nodal involvement or
disease left behind is warranted. It
is hoped that studies will continue
that can lead to comparative information pertinent to evidence of objective regression of disease and
the practical reality of increased
survival.
Summary
5-Fluorouracil (5-FU) is the best
agent for the treatment of a ll gastrointestinal cancers but should be
used with restraint, since severe
toxicity does not guarantee increased response or survival time.
Experimental work suggests that
glucose enhances cellular upta ke of
5-FU. Alkyl ating agents are definitely useful and occasionally produce long-term responses. Mitomycin C shows activity but is not
available. There are reports of responses to methotrexate, vinca alkaloids, and mithramycin, but their
place in the m an agement of gastrointestinal cancer is not established .
The usefulness of alkyl ating agents
or 5-FU as adjuvants to surgery is
not clear, but evidence is accumulating which supports the adjuvant
use of 5-FU when disease is left
behind. There is laboratory evidence that anticoagulation ca n prevent tumor recurrence, and this
should be studied further. The best
combination chemotherapy has not
been determined. Regional chemotherapy offers a logical approach,
but comparative data with systemic
treatment are lacking, although
techniques for protracted infusion,
particularly of primary a nd secondary hepatic tumors, m ay justify its
increased use. Wound washing with
available contact tumoricidal agents
is contraindicated, as it may increase local recurrence.
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CORRECTION: Vol. 3, No. 1
(Spring), 1967, p. 36. In table 1,
a number of stage I patients included in the period from 1955 to
1960 were treated surgically (with
or without additional irradiation) ~
most, however, were irradiated
only. Stage II through IV patients
received irradiation only.

